Mecklenbrauck, Rabea
Heuser, Michael
Funding for this research was provided by:
Medizinische Hochschule Hannover (MHH)
Article History
Received: 21 August 2022
Accepted: 12 October 2022
First Online: 1 November 2022
Declarations
:
: Michael Heuser has to declare the following conflicts of interest: Honoraria: Abbvie, Eurocept, Jazz Pharmaceuticals, Janssen, Novartis, Takeda Consultancy: Abbvie, Agios, BMS, Daiichi Sankyo, Glycostem, Jazz Pharmaceuticals, Kura Oncology, Novartis, Pfizer, PinotBio, Roche, Tolremo Research funding for institution: Abbvie, Agios, Astellas, Bayer Pharma AG, BergenBio, Daiichi Sankyo, Glycostem, Jazz Pharmaceuticals, Loxo Oncology, Novartis, Pfizer, PinotBio, Roche Rabea Mecklenbrauck has no conflicts of interest to declare.